Clinical Trials for Mesothelioma Patients—A Study of Azacitidine in combination with Temo/Azac

Read about a current clinical trial about the use of a Phase I dose study of Azacitidine in combination with Temo/Azac for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Phase I Dose-Escalation Study of Azacitidine In Combination With Temozolomide (Temo/Azac)

Purpose

The purpose of this study is to determine safety and toxicity for the combination of Temozolomide and Azacitidine in the treatment of Advanced Soft Tissue Sarcoma or Malignant Mesothelioma. This is a single-center, open-label, single-arm Phase I dose-escalation trial. Patients will be evaluated with complete history and physical as well as laboratory studies (complete blood count, metabolic panel, liver function tests), biopsy, and imaging of all sites of measurable disease. This study will be conducted over the course of 3 years.

Phase, Condition and Intervention:

Phase I; Soft Tissue Sarcoma, Mesothelioma; Drug: Azacitidine In Combination With Temozolomide

Study Type and Design:

Interventional; Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study

Official Title:

A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.